Insurance applications for psychedelic-assisted therapy can be denied at multiple levels — private insurance prior auth, VAC (Veterans Affairs Canada) mental-health benefits, WSIB (Ontario's Workplace Safety and Insurance Board)/WCB (Workers' Compensation Board) workers' compensation, provincial drug-plan exceptional access, and Alberta Blue Cross PAT (Psychedelic-Assisted Therapy). Most denials are appealable. Successful appeals typically involve additional clinical documentation (more detailed antidepressant trial history; specialist consultation letters; alternative treatment failure documentation), process navigation (insurer-specific appeal procedures), and sometimes pathway switching (e.g., from off-label ketamine to Spravato; from psilocybin SAP to ketamine therapy with broader access). This article walks through the appeal landscape across major Canadian insurance pathways and explains practical strategies for patients facing denials.

Key takeaways

Most denials are appealable. Private insurance prior-auth, VAC, WSIB/WCB, and provincial exceptional-access pathways have appeal processes.

Successful appeals typically involve: additional clinical documentation; specialist consultation letters; alternative treatment failure documentation; updated severity scores.

Common denial reasons: insufficient antidepressant trial documentation; lack of Janssen Journey certification; plan-specific exclusions; documentation timeline issues.

Pathway switching is often a practical alternative: if Spravato prior auth is denied, off-label ketamine therapy may be more accessible (though typically out-of-pocket); if psilocybin SAP is denied, ketamine therapy with VAC/WSIB pathways may apply.

Patient advocacy resources: TheraPsil, MAPS Canada, PsyCan, specialized health-insurance lawyers, provincial ombudsperson offices.

ATMA CENA's intake call discusses the realistic alternative pathways if your primary application is denied.

Common reasons for denial

Understanding why applications are denied is the first step to successful appeals. Common reasons across major Canadian psychedelic-assisted therapy insurance pathways:

Documentation issues

Insufficient antidepressant trial documentation: dose or duration not clearly documented as adequate (≥therapeutic dose for ≥6 weeks per CANMAT (Canadian Network for Mood and Anxiety Treatments))
Lack of severity documentation: missing PHQ-9, MADRS, HAM-D scores at decision point
Missing specialist consultation: psychiatric evaluation not documented for non-psychiatric prescriber requests
Trial timeline issues: trials documented as too long ago to count in current episode

Process / procedural

Wrong form or wrong prior-auth pathway for the specific insurer
Missing release of medical information
Incomplete provider certification: e.g., Janssen Journey not confirmed for Spravato
Plan-specific exclusions that the application didn't account for

Coverage-criteria mismatch

Off-label use: applications for off-label generic ketamine for psychiatric use typically denied at private insurers (no approved indication)
Indication mismatch: e.g., Spravato application for PTSD specifically (Spravato is TRD-only-approved)
MDMA or psilocybin requests through pathways without those substances on formulary

Substantive clinical disagreement

Insurer believes alternative treatments not adequately tried: ECT, augmentation, additional antidepressant classes
Insurer believes diagnosis not adequately documented
Cost-effectiveness concerns — particularly for higher-cost pathways

Private insurance prior-auth appeals (Manulife, Sun Life, Green Shield, Blue Cross)

For Spravato prior-auth denials at private extended-health insurers:

Step 1: Read the denial letter carefully

Identify the specific reason for denial. Insurers must provide written explanation. Determine whether the issue is documentation, procedural, or substantive clinical disagreement.

Step 2: Compile additional documentation

Strong appeal documentation typically includes:

More granular antidepressant trial history: each medication, exact dose, duration, response/non-response, side effects, reasons for discontinuation
Specialist consultation letter: from prescribing psychiatrist or another specialist supporting clinical rationale
Alternative treatment failure documentation: ECT, IV ketamine off-label, augmentation strategies — where applicable
Updated severity documentation: current PHQ-9, MADRS scores
Provider certification verification: Janssen Journey confirmation for Spravato
Treatment plan with specific goals: response criteria, expected duration, monitoring framework

Step 3: Submit through insurer's appeal process

Each insurer has specific appeal procedures. Documents the patient typically signs:

Consent for medical-information release
Authorization for prescribing physician communication with insurer

Step 4: If first appeal denied, escalate

Most insurers have second-level appeal processes — sometimes involving a third-party medical review board. Specialized health-insurance lawyers can support complex appeals.

Step 5: Consider pathway switching

If appeals fail:

Off-label ketamine therapy may be more accessible (though typically out-of-pocket) — see Ketamine Therapy Cost in Canada
ATMA CENA's KAT pricing tiers apply: $1,530–$6,930 per program

PSHCP / Canada Life Form M7520 appeals

For PSHCP federal public servants:

First-level appeal: resubmit with additional documentation (typically antidepressant trial granularity, specialist letters)
Second-level appeal: Canada Life formal appeal process — typically requires more detailed clinical justification
Public Service Health Care Plan administrative reviews: rare but available for complex cases

For PSHCP-specific context: PSHCP / Canada Life Spravato Coverage.

VAC appeals (Veterans Affairs Canada)

For veterans whose mental-health benefits applications are denied:

VAC review process

VAC has documented appeal mechanisms:

VAC Review and Appeal Process: includes VRAB (Veterans Review and Appeal Board) for service-connection determinations and benefit eligibility
Reconsideration requests: based on new information or evidence
Federal Court appeals for unresolved disputes (rare; complex cases)

Strong appeal documentation

Medical board / specialist evaluations
Detailed service-connection documentation
Conventional treatment failure across multiple modalities
Updated clinical severity assessments

Patient advocacy

VAC Bureau of Pensions Advocates (BPA) provides free legal advice and representation
Specialized veteran-advocacy law firms for complex cases
Royal Canadian Legion service officers assist with claims and appeals

For VAC-specific context: VAC Coverage for Psychedelic-Assisted Therapy, MDMA-Assisted Therapy for Veterans.

WSIB Ontario / WCB Alberta appeals

For workers' compensation denials:

WSIB Ontario

Operational decision review: first-level reconsideration
WSIAT (Workplace Safety and Insurance Appeals Tribunal): independent appeal body for unresolved disputes
OWA (Office of the Worker Adviser): free advice and representation for non-unionized workers

WCB Alberta

Internal review: first-level reconsideration of decisions
Appeals Commission: independent appeal body
Office of the Appeals Advisor: free advice for workers

Other provincial WCBs

Each provincial workers' compensation board has appeal mechanisms with varying processes.

For workers' compensation context: Workers' Compensation for Psychedelic-Assisted Therapy.

Provincial drug-plan exceptional access denials

For ODB EAP, BC PharmaCare Special Authority, and similar provincial exceptional-access denials:

Resubmit with additional clinical justification: typically a higher bar than private insurance given the Do Not Reimburse recommendation context
Provincial ombudsperson offices for substantive complaints
Realistic outcome: provincial exceptional-access for psychedelic-assisted therapy is rarely approved; most patients eventually pursue alternative coverage pathways

For provincial coverage context: Provincial Drug Plans for Psychedelic Therapy.

SAP application denials (psilocybin, MDMA)

For Health Canada SAP requests denied:

Resubmit with additional documentation: more detailed conventional treatment failures; specialist consultation; updated clinical context
Identify a different prescribing physician if the original prescriber's application had structural issues
Pursue alternative pathways: ketamine therapy (broader access) for many indications; ECT for severe TRD; standard PTSD pharmacotherapy with augmentation

For SAP context: How to Access Psilocybin Therapy in Canada and How to Access MDMA-Assisted Therapy in Canada.

Pathway switching as practical alternative

For many patients, pathway switching is the realistic response to denials:

If Spravato prior auth denied → off-label ketamine

Pros: more broadly accessible; lower per-session cost ($375–$1,000 IV); ATMA CENA KAT pricing tiers
Cons: typically out-of-pocket; no equivalent insurance coverage

If psilocybin SAP denied → ketamine therapy

Pros: ketamine has broader Canadian access (off-label legal); established VAC/WSIB/WCB coverage; Spravato Health Canada-approved
Cons: smaller PTSD-specific effect sizes than MDMA; smaller end-of-life evidence than psilocybin

If MDMA-AT SAP denied → ketamine therapy for PTSD

Pros: established VAC coverage; broader Canadian access; faster timeline
Cons: smaller PTSD effect sizes (Bryant 2024 g≈0.20 bias-corrected vs MDMA Mitchell 2021/2023 d≈0.91-1.0)

If VAC denied → workers' compensation or private pathway

For service-connected first responders with workplace exposure: WSIB/WCB pathways
For private-benefits-eligible: private prior auth or out-of-pocket

For substance-comparison context: MDMA vs Ketamine for PTSD, Psilocybin vs Ketamine Therapy, Ketamine vs Spravato.

Patient advocacy resources

TheraPsil — patient consultation for SAP-pathway psilocybin and MDMA
MAPS Canada — Canadian psychedelic-medicine advocacy
PsyCan / Psychedelics Canada — trade association advocacy
Specialized health-insurance lawyers — for complex private insurance and WSIB/WCB appeals
VAC Bureau of Pensions Advocates — free advocacy for veterans
Office of the Worker Adviser (Ontario) — free advice for non-unionized workers
Provincial ombudsperson offices — for unresolved insurance disputes
ATMA CENA's intake call — practical alternative-pathway orientation

Frequently asked questions

Can I appeal a denied prior auth? Yes. Most insurers have appeal processes. Specific procedures vary; insurer-specific documentation supports successful appeals.

What documentation supports successful appeals? Detailed antidepressant trial history; specialist consultation letters; alternative treatment failure documentation; updated severity scores; provider certification verification.

How long does an appeal take? Varies. Private insurer first-level appeals: typically 2–6 weeks. WSIB/WCB appeals: weeks to months depending on level. VAC appeals: months to years for complex cases.

Can I get legal help? Yes. Specialized health-insurance lawyers, VAC Bureau of Pensions Advocates, Office of the Worker Adviser, and patient advocacy organizations can support complex appeals.

What if my Spravato prior auth is denied? First-level appeal with additional documentation. If unsuccessful, second-level appeal. If still unsuccessful, alternative pathways including off-label ketamine therapy (typically out-of-pocket).

What if my psilocybin SAP is denied? Resubmit with additional documentation, identify alternative prescribing physician if needed, or pursue ketamine therapy with broader access.

What if my VAC application is denied? VAC Review and Appeal Process. Bureau of Pensions Advocates provides free advocacy. Reconsideration requests for new information. Federal Court appeals for unresolved disputes.

What if my WSIB application is denied? Operational decision review first. Workplace Safety and Insurance Appeals Tribunal for unresolved disputes. Office of the Worker Adviser provides free advice.

Can my employer fire me for using psychedelic-assisted therapy? Generally no — employment-protection laws apply. SAP-pathway psilocybin or MDMA is legal therapeutic care; off-label ketamine is legal physician-prescribed care. Specific employment situations vary; consult employment lawyers for specific concerns.

Is there any situation where appeals reliably succeed? Documentation issues with clear correction (missing dose/duration documentation; missing severity scores) typically have higher appeal success than substantive clinical disagreements. Procedural issues (wrong form, missing certifications) typically resolve with corrected resubmission.

How does ATMA CENA support patients facing denials? ATMA CENA's intake call discusses realistic alternative pathways if primary applications are denied. ATMA CENA can also support documentation efforts in coordination with prescribing physicians.

Can I switch from Spravato to off-label ketamine? Discuss with prescribing physician. Off-label ketamine has broader Canadian access (off-label legal) but typically out-of-pocket. ATMA CENA's KAT pricing tiers apply.

What if I can't afford psychedelic-assisted therapy and have no coverage? Out-of-pocket pathways with payment plans (some clinics offer financing); explore alternative pathways including the Edmonton public IV ketamine program for ultra-resistant TRD Albertans; consider broader treatment alternatives discussed with prescribing psychiatrist.

Sources

Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
VAC Bureau of Pensions Advocates: https://www.veterans.gc.ca/eng/contact/bureau-pensions-advocates
WSIB Ontario Appeals Information: https://www.wsib.ca/en/businesses/claims/appealing-decision
Workplace Safety and Insurance Appeals Tribunal (Ontario): https://www.wsiat.on.ca/
Office of the Worker Adviser (Ontario): https://www.owa.gov.on.ca/
WCB Alberta Appeals Commission: https://www.appealscommission.ab.ca/
CDA-AMC: https://www.cda-amc.ca/
TheraPsil: https://therapsil.ca/

Last updated: 2026-05-06

Insurance Appeals When Coverage Is Denied

Coverage rules differ by payer